Preparation & Measurement Guide

Thymosin Alpha-1 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Thymosin Alpha-1 10mg vial.

Research use only Educational comparator summary. This research material is not an approved drug product.
Vial Size Thymosin Alpha-1 10mg
Preparation 2mL bacteriostatic water
Concentration 5mg/mL after preparation
Documented Convention 1.6mg twice weekly

1. Preparation and Measurement

Thymosin Alpha-1 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in published clinical research. Frequency: twice weekly.

Period Documented amount Measurement
Weeks 1-12 1.6mg twice weekly 0.32mL / 32 units

Vial estimate: One 10mg vial contains approximately 6 documented-size administrations at 1.6mg.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Thymosin Alpha-1 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Thymosin alpha-1 has been examined in clinical studies involving immune regulation, infection, and inflammatory responses. Results vary by condition, study design, and background treatment.

The 1.6mg convention appears in published clinical research, but this research material is not an approved drug product and should not be treated as equivalent to a regulated formulation.

Primary Research and Regulatory References

  1. Thymosin alpha-1 clinical research review (2022)
  2. Thymosin alpha-1 randomized clinical study
  3. Thymosin alpha-1 sepsis trial and evidence limitations

Research Materials

Review Thymosin Alpha-1 10mg Product Information

← Back to Dosage Protocols

Research-use disclaimer: Thymosin Alpha-1 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.